Form 4: Natera Executive Solomon Moshkevich Sells Shares Under 10b5-1 Trading Plan

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., executed multiple sales of common stock on May 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 1, 2025, Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold shares of Natera common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• A total of 3,000 shares were sold in multiple transactions at varying weighted average prices.
• The prices ranged from $147.83 to $152.04 per share.
• Following the reported transactions, Moshkevich directly owns 136,205 shares of Natera common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports stock sales under a pre-existing trading plan, which is a routine event. There's no indication of positive or negative implications for the company's performance.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information. Investors often monitor insider transactions for signals about a company's prospects, but pre-planned sales are generally less informative.

Comparison to Industry Standards

• Executive compensation packages often include stock options and grants, leading to periodic sales.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also see insider trading activity as part of their executive compensation programs.
• The volume and frequency of insider sales are generally compared to historical patterns and industry peers to assess significance.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they interpret the sales negatively, although the 10b5-1 plan mitigates this.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates

Keywords

Natera, NTRA, Solomon Moshkevich, insider trading, Form 4, stock sale, Rule 10b5-1, clinical diagnostics